{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T09:46:02Z","timestamp":1785923162062,"version":"3.56.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Direct oral anticoagulants (DOACs) are frequently co-prescribed with angiotensin II receptor blockers (ARBs) in atrial fibrillation (AF). Because ARBs differ in P-glycoprotein (P-gp) inhibition, bleeding risk may vary. We compared major bleeding when DOACs were combined with telmisartan (high P-gp inhibition) versus olmesartan (low P-gp inhibition). We conducted a nationwide cohort study from 2016\u20132023 in Korea. We identified AF patients who started a DOAC with telmisartan or olmesartan. The primary outcome was a composite of intracranial hemorrhage and gastrointestinal bleeding. Secondary outcomes included each component of the primary outcome and ischemic stroke. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using Cox proportional hazards models. Among DOAC-treated patients with AF, 27,851 and 20,010 patients were included in the telmisartan and olmesartan groups, respectively. The incidence rates of the primary outcome were 9.13 per 1000 person-years in the telmisartan group and 6.69 in the olmesartan group (HR 1.35, 95% CI 1.11\u20131.65). Concomitant use of telmisartan was associated with a higher risk of gastrointestinal bleeding (1.49, 1.17\u20131.89), but not with intracranial hemorrhage (1.06, 0.74\u20131.54) or ischemic stroke (0.94, 0.78\u20131.14). Among patients with AF using DOACs, concomitant use of ARBs with high P-gp inhibitory activity was associated with a significantly higher risk of major bleeding and gastrointestinal bleeding compared\u2013ARBs with low P-gp inhibitory activity. These findings suggest that differences in P-gp inhibitory activity among ARBs may influence bleeding risk in clinical practice when co-administered with DOACs.<\/jats:p>","DOI":"10.1038\/s41440-026-02712-7","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T03:38:03Z","timestamp":1781667483000},"page":"2318-2328","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Comparative bleeding risk between angiotensin II receptor blockers with high versus low P-glycoprotein inhibitory activity in patients with atrial fibrillation receiving direct oral anticoagulants"],"prefix":"10.1038","volume":"49","author":[{"given":"Seonji","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seng Chan","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung","family":"Il Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Hwan","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong-Il","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sungha","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"key":"2712_CR1","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1001\/jamainternmed.2019.2431","volume":"179","author":"JD Douketis","year":"2019","unstructured":"Douketis JD, Spyropoulos AC, Duncan J, Carrier M, Le Gal G, Tafur AJ, et al. Perioperative management of patients with atrial fibrillation receiving a direct oral anticoagulant. JAMA Intern Med. 2019;179:1469\u201378.","journal-title":"JAMA Intern Med"},{"key":"2712_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s40885-024-00262-z","volume":"30","author":"HC Kim","year":"2024","unstructured":"Kim HC, Lee H, Lee H-H, Son D, Cho M, Shin S, et al. Korea Hypertension Fact Sheet 2023: analysis of nationwide population-based data with a particular focus on hypertension in special populations. Clin Hypertens. 2024;30:7.","journal-title":"Clin Hypertens"},{"key":"2712_CR3","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.jacc.2018.05.066","volume":"72","author":"S-R Lee","year":"2018","unstructured":"Lee S-R, Choi E-K, Han K-D, Jung J-H, Oh S, Lip GY. Edoxaban in Asian patients with atrial fibrillation: effectiveness and safety. J Am Coll Cardiol. 2018;72:838\u201353.","journal-title":"J Am Coll Cardiol"},{"key":"2712_CR4","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1161\/STROKEAHA.119.025536","volume":"50","author":"S-R Lee","year":"2019","unstructured":"Lee S-R, Choi E-K, Kwon S, Han K-D, Jung J-H, Cha M-J, et al. Effectiveness and safety of contemporary oral anticoagulants among Asians with nonvalvular atrial fibrillation. Stroke. 2019;50:2245\u20139.","journal-title":"Stroke"},{"key":"2712_CR5","doi-asserted-by":"publisher","first-page":"e004075","DOI":"10.1161\/JAHA.116.004075","volume":"5","author":"E Kodani","year":"2016","unstructured":"Kodani E, Atarashi H, Inoue H, Okumura K, Yamashita T, Otsuka T, et al. Impact of blood pressure control on thromboembolism and major hemorrhage in patients with nonvalvular atrial fibrillation: a subanalysis of the J-RHYTHM Registry. J Am Heart Assoc. 2016;5:e004075.","journal-title":"J Am Heart Assoc"},{"key":"2712_CR6","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1161\/HYPERTENSIONAHA.119.13138","volume":"74","author":"S Park","year":"2019","unstructured":"Park S, Bergmark BA, Shi M, Lanz H-J, Chung N, Ruff CT, et al. Edoxaban versus warfarin stratified by average blood pressure in 19 679 patients with atrial fibrillation and a history of hypertension in the ENGAGE AF-TIMI 48 trial. Hypertension. 2019;74:597\u2013605.","journal-title":"Hypertension"},{"key":"2712_CR7","doi-asserted-by":"publisher","first-page":"769","DOI":"10.7326\/M22-3238","volume":"176","author":"WA Ray","year":"2023","unstructured":"Ray WA, Chung CP, Stein CM, Smalley W, Zimmerman E, Dupont WD, et al. Risk for bleeding-related hospitalizations during use of amiodarone with apixaban or rivaroxaban in patients with atrial fibrillation: a retrospective cohort study. Ann Intern Med. 2023;176:769\u201378.","journal-title":"Ann Intern Med"},{"key":"2712_CR8","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1177\/1753944712444866","volume":"6","author":"P Verdecchia","year":"2012","unstructured":"Verdecchia P, Gentile G, Angeli F, Reboldi G. Beyond blood pressure: evidence for cardiovascular, cerebrovascular, and renal protective effects of renin\u2013angiotensin system blockers. Therapeutic Adv Cardiovasc Dis. 2012;6:81\u201391.","journal-title":"Therapeutic Adv Cardiovasc Dis"},{"key":"2712_CR9","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1161\/HYPERTENSIONAHA.120.16667","volume":"78","author":"R Chen","year":"2021","unstructured":"Chen R, Suchard MA, Krumholz HM, Schuemie MJ, Shea S, Duke J, et al. Comparative first-line effectiveness and safety of ACE (angiotensin-converting enzyme) inhibitors and angiotensin receptor blockers: a multinational cohort study. Hypertension. 2021;78:591\u2013603.","journal-title":"Hypertension"},{"key":"2712_CR10","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1093\/europace\/euab065","volume":"23","author":"J Steffel","year":"2021","unstructured":"Steffel J, Collins R, Antz M, Cornu P, Desteghe L, Haeusler KG, et al. 2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. EP Europace. 2021;23:1612\u201376.","journal-title":"EP Europace"},{"key":"2712_CR11","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1007\/s00392-015-0936-y","volume":"105","author":"M Proietti","year":"2016","unstructured":"Proietti M, Raparelli V, Olshansky B, Lip GY. Polypharmacy and major adverse events in atrial fibrillation: observations from the AFFIRM trial. Clin Res Cardiol. 2016;105:412\u201320.","journal-title":"Clin Res Cardiol"},{"key":"2712_CR12","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.3390\/pharmaceutics14061120","volume":"14","author":"N Ferri","year":"2022","unstructured":"Ferri N, Colombo E, Tenconi M, Baldessin L, Corsini A. Drug-drug interactions of direct oral anticoagulants (DOACs): from pharmacological to clinical practice. Pharmaceutics. 2022;14:1120.","journal-title":"Pharmaceutics"},{"key":"2712_CR13","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1093\/ehjcvp\/pvad070","volume":"9","author":"M Grymonprez","year":"2023","unstructured":"Grymonprez M, Carnoy L, Capiau A, Boussery K, Mehuys E, De Backer TL, et al. Impact of P-glycoprotein and CYP3A4-interacting drugs on clinical outcomes in patients with atrial fibrillation using non-vitamin K antagonist oral anticoagulants: a nationwide cohort study. Eur Heart J Cardiovasc Pharmacother. 2023;9:722\u201330.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2712_CR14","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.124.038668","volume":"14","author":"CK Wong","year":"2025","unstructured":"Wong CK, Wong YK, Chan YH, Lin M, Hai JSH, Yiu KH, et al. Concomitant Drug Interactions With Non\u2013Vitamin K Oral Anticoagulants Are Associated With Bleeding and Mortality Risk in Patients With Nonvalvular Atrial Fibrillation. J Am Heart Assoc. 2025;14:e038668.","journal-title":"J Am Heart Assoc"},{"key":"2712_CR15","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1517\/17425255.2010.494597","volume":"6","author":"S Deppe","year":"2010","unstructured":"Deppe S, B\u00f6ger RH, Weiss J, Benndorf RA. Telmisartan: a review of its pharmacodynamic and pharmacokinetic properties. Expert Opin drug Metab Toxicol. 2010;6:863\u201371.","journal-title":"Expert Opin drug Metab Toxicol"},{"key":"2712_CR16","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.lfs.2009.11.006","volume":"86","author":"E Kamiyama","year":"2010","unstructured":"Kamiyama E, Nakai D, Mikkaichi T, Okudaira N, Okazaki O. Interaction of angiotensin II type 1 receptor blockers with P-gp substrates in Caco-2 cells and hMDR1-expressing membranes. Life Sci. 2010;86:52\u20138.","journal-title":"Life Sci"},{"key":"2712_CR17","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1124\/pr.112.007278","volume":"65","author":"MC Michel","year":"2013","unstructured":"Michel MC, Foster C, Brunner HR, Liu L. A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists. Pharmacol Rev. 2013;65:809\u201348.","journal-title":"Pharmacol Rev"},{"key":"2712_CR18","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1016\/j.jacc.2013.02.058","volume":"61","author":"JD Wessler","year":"2013","unstructured":"Wessler JD, Grip LT, Mendell J, Giugliano RP. The P-glycoprotein transport system and cardiovascular drugs. J Am Coll Cardiol. 2013;61:2495\u2013502.","journal-title":"J Am Coll Cardiol"},{"key":"2712_CR19","doi-asserted-by":"publisher","first-page":"718","DOI":"10.3346\/jkms.2017.32.5.718","volume":"32","author":"J-A Kim","year":"2017","unstructured":"Kim J-A, Yoon S, Kim L-Y, Kim D-S. Towards actualizing the value potential of Korea Health Insurance Review and Assessment (HIRA) data as a resource for health research: strengths, limitations, applications, and strategies for optimal use of HIRA data. J Korean Med Sci. 2017;32:718.","journal-title":"J Korean Med Sci"},{"key":"2712_CR20","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1093\/eurheartj\/ehx316","volume":"38","author":"SS Lee","year":"2017","unstructured":"Lee SS, Ae Kong K, Kim D, Lim Y-M, Yang P-S, Yi J-E, et al. Clinical implication of an impaired fasting glucose and prehypertension related to new onset atrial fibrillation in a healthy Asian population without underlying disease: a nationwide cohort study in Korea. Eur Heart J. 2017;38:2599\u2013607.","journal-title":"Eur Heart J"},{"key":"2712_CR21","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.ahj.2018.04.017","volume":"202","author":"D Kim","year":"2018","unstructured":"Kim D, Yang P-S, Jang E, Yu HT, Kim T-H, Uhm J-S, et al. 10-year nationwide trends of the incidence, prevalence, and adverse outcomes of non-valvular atrial fibrillation nationwide health insurance data covering the entire Korean population. Am Heart J. 2018;202:20\u20136.","journal-title":"Am Heart J"},{"key":"2712_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s42444-019-0005-0","volume":"20","author":"J Park","year":"2019","unstructured":"Park J, Kwon S, Choi E-K, Choi Y-j, Lee E, Choe W, et al. Validation of diagnostic codes of major clinical outcomes in a National Health Insurance database. Int J Arrhythmia. 2019;20:1\u20137.","journal-title":"Int J Arrhythmia"},{"key":"2712_CR23","unstructured":"WHO. Collaborating centre for drug statistics methodology, guidelines for ATC classification and DDD assignment. vol. 18, WHO Collaborating Centre for Drug Statistics Methodology; 2000."},{"key":"2712_CR24","doi-asserted-by":"crossref","unstructured":"Kozma CM, Dickson M, Phillips AL, Meletiche DM. Medication possession ratio: implications of using fixed and variable observation periods in assessing adherence with disease-modifying drugs in patients with multiple sclerosis. Patient Prefer Adherence. 2013;7:509\u201316.","DOI":"10.2147\/PPA.S40736"},{"key":"2712_CR25","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1093\/ehjqcco\/qcab002","volume":"8","author":"RK Sandhu","year":"2022","unstructured":"Sandhu RK, Islam S, Dover DC, Andrade JG, Ezekowitz J, McAlister FA, et al. Concurrent use of P-glycoprotein or Cytochrome 3A4 drugs and non-vitamin K antagonist oral anticoagulants in non-valvular atrial fibrillation. Eur Heart J Qual Care Clin Outcomes. 2022;8:195\u2013201.","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"2712_CR26","doi-asserted-by":"publisher","first-page":"3039","DOI":"10.1111\/bcp.15265","volume":"88","author":"M Grymonprez","year":"2022","unstructured":"Grymonprez M, Vanspranghe K, Capiau A, Boussery K, Steurbaut S, Lahousse L. Impact of P-glycoprotein and\/or CYP3A4-interacting drugs on effectiveness and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: A meta-analysis. Br J Clin Pharmacol. 2022;88:3039\u201351.","journal-title":"Br J Clin Pharmacol"},{"key":"2712_CR27","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s00228-020-03015-7","volume":"77","author":"J Holm","year":"2021","unstructured":"Holm J, Mannheimer B, Malmstr\u00f6m RE, Eliasson E, Lindh JD. Bleeding and thromboembolism due to drug-drug interactions with non-vitamin K antagonist oral anticoagulants\u2014a Swedish, register-based cohort study in atrial fibrillation outpatients. Eur J Clin Pharmacol. 2021;77:409\u201319.","journal-title":"Eur J Clin Pharmacol"},{"key":"2712_CR28","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1111\/bcp.14227","volume":"86","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Souverein PC, Gardarsdottir H, van den Ham HA, Maitland-van der Zee AH, de Boer A. Risk of major bleeding among users of direct oral anticoagulants combined with interacting drugs: a population-based nested case\u2013control study. Br J Clin Pharmacol. 2020;86:1150\u201364.","journal-title":"Br J Clin Pharmacol"},{"key":"2712_CR29","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1002\/bdd.699","volume":"31","author":"J Wei\u00df","year":"2010","unstructured":"Wei\u00df J, Sauer A, Divac N, Herzog M, Schwedhelm E, B\u00f6ger RH, et al. Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters. Biopharm Drug Dispos. 2010;31:150\u201361.","journal-title":"Biopharm Drug Dispos"},{"key":"2712_CR30","doi-asserted-by":"crossref","unstructured":"Liang Y, Yang Q, Zhu J, Eikelboom J. Bleeding risk in Asian patients: potential for thrombin amplification pathway blockade using factor XI inhibitors. Vol 4. American College of Cardiology Foundation Washington DC; 2024, pp. 163\u20135.","DOI":"10.1016\/j.jacasi.2023.11.014"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41440-026-02712-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-026-02712-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-026-02712-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T09:06:11Z","timestamp":1785920771000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41440-026-02712-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["2712"],"URL":"https:\/\/doi.org\/10.1038\/s41440-026-02712-7","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,17]]},"assertion":[{"value":"16 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SCY reports grants from Daiichi Sankyo. He is a coinventor of granted Korean patents DP-2023-1223 and DP-2023-0920 and has pending Patent Applications DP-2024-0909, DP-2024-0908, DP-2022-1658, DP-2022-1478, and DP-2022-1365, unrelated to the current work. SCY is the Chief Executive Officer of PHI Digital Healthcare. J-IC received consulting, speaker, or teaching fees or honoraria from Abbott, Biosense Wester Inc, Boehringer Ingelheim, Chong Kun Dang, Daewoong Pharmaceutical Co., Ltd., Daiichi Sankyo, Hanmi Pharmaceutical, I.SigNal, Medtronic, Mezoo Co., Ltd., Novartis, Roche, Samjin Pharmaceutical Co., Ltd., Sanofi, Viatris, and Yuhan; research grants from Chong Kun Dang, Samjin Pharmaceutical, and Sanofi. SP received honoraria from Viatris, Organon, Boryoung, Hanmi, Daewoong, Donga, Celltrion, Servier, Daiichi Sankyo, Chong Kun Dang, Handok and Daewon, a research grant from Daiichi Sankyo, consultation fee from Skylab, and stock from Mediwhale. J-HB is a full-time employee of Daiichi Sankyo Korea. The other authors report no conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}}]}}